内皮细胞活化和应激指数（EASIX）评分是弥漫性大 B 细胞淋巴瘤患者的独立预后因素。
The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma.
机构信息
Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, South Korea.
Division of Hematology and Oncology, Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, South Korea.
出版信息
BMC Cancer. 2022 Jul 25;22(1):816. doi: 10.1186/s12885-022-09915-4.
BACKGROUND
The endothelial activation and stress index (EASIX) score has been reported to predict overall survival (OS) in hematological cancers. However, it has not been validated as a prognostic marker for diffuse large B-cell lymphoma (DLBCL) to date.
METHODS
The records of 265 patients who presented with DLBCL in the Republic of Korea between January 07, 2004, and March 05, 2020 were retrospectively reviewed. For all included patients, EASIX scores were calculated using serum lactate dehydrogenase (LDH) and creatinine levels and the platelet count measured at diagnosis as follows: LDH (U/L) × creatinine (mg/dL)/platelet count (10/L).
RESULTS
The median age of the patients was 64 years. The optimal cutoff value of EASIX according to the receiver operating characteristic analysis for OS was 1.33. All the patients were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone combined with rituximab. The 1-year OS and progression-free survival (PFS) rates were lower in the high-EASIX group than in the low EASIX group (63.8% vs. 84.4%, p < 0.001 and 54.0% vs. 79.6%, p < 0.001, respectively). A high EASIX was an independent poor prognostic factor for OS and PFS (hazard ratio, 1.606; 95% CI, 1.077-2.395; p = 0.020 and hazard ratio, 1.621; 95% CI, 1.066-2.464; p = 0.024, respectively).
CONCLUSIONS
EASIX is a readily available and cheaply obtainable parameter in clinical studies and shows considerable potential as a new prognostic marker for patients with newly diagnosed DLBCL.
背景
内皮细胞激活和应激指数（EASIX）评分已被报道可预测血液系统恶性肿瘤的总生存期（OS）。然而，迄今为止，它尚未被验证为弥漫性大 B 细胞淋巴瘤（DLBCL）的预后标志物。
方法
回顾性分析了 2004 年 1 月 7 日至 2020 年 3 月 5 日期间在韩国就诊的 265 例 DLBCL 患者的记录。对于所有纳入的患者，使用血清乳酸脱氢酶（LDH）和肌酐水平以及诊断时测量的血小板计数计算 EASIX 评分，公式为：LDH（U/L）×肌酐（mg/dL）/血小板计数（10/L）。
结果
患者的中位年龄为 64 岁。根据 OS 的受试者工作特征分析，EASIX 的最佳截断值为 1.33。所有患者均接受环磷酰胺、多柔比星、长春新碱和泼尼松联合利妥昔单抗治疗。高 EASIX 组的 1 年 OS 和无进展生存期（PFS）率低于低 EASIX 组（63.8% vs. 84.4%，p<0.001 和 54.0% vs. 79.6%，p<0.001）。高 EASIX 是 OS 和 PFS 的独立不良预后因素（风险比，1.606；95%可信区间，1.077-2.395；p=0.020 和风险比，1.621；95%可信区间，1.066-2.464；p=0.024）。
结论
EASIX 是临床研究中易于获得且价格低廉的参数，作为新诊断的 DLBCL 患者的新预后标志物具有很大的潜力。
Zotero 插件